BACKGROUND A previous comparative study in Japan has demonstrated that the two consecutive UroVysion tests are useful tools to detect the presence of bladder cancer during follow-up after transurethral resection, but they also presented their high rates of false-positive results. Here, we aimed to evaluate the relationship between the UroVysion tests and subsequent intravesical recurrence. METHODS In the previous study, patients without bladder cancer during the first analysis showed the same examination set repeated 3 months later as the second analysis. In this follow-up study, 326 patients showed negative findings confirmed on cystoscopy during the second UroVysion test. Recurrence-free survival was assessed using a median follow-up of 27 months. RESULTS In the two consecutive UroVysion tests, 214 patients (65.6%) showed negative UroVysion results in both tests, whereas 91 presented a positive result on either tests and 21 patients presented positive results in both tests. During the follow-up, 40 patients (12.3%) had an intravesical recurrence with non-muscle-invasive bladder cancer. The recurrence rates in patients with negative results in both tests, those with one positive result in either tests, and those with positive results in both tests were 8.4%, 16.5%, and 33.3%, respectively. The multivariate analysis indicated that the history of bladder cancer and the consecutive UroVysion test pattern were independent risk factors for recurrence. CONCLUSIONS Our data confirmed the effectiveness of two consecutive UroVysion tests in predicting intravesical recurrence after TURBT. Further prospective studies would help determine an appropriate interval for cystoscopy follow-up.

中文翻译：

---

根据两次连续 UroVysion 荧光原位杂交测试的结果分层膀胱癌膀胱内复发的风险：日本的一项前瞻性随访研究。

背景 之前在日本进行的一项比较研究表明，连续两次 UroVysion 测试是在经尿道切除术后随访期间检测膀胱癌存在的有用工具，但它们也存在较高的假阳性结果。在这里，我们旨在评估 UroVysion 测试与随后的膀胱内复发之间的关系。方法 在之前的研究中，在第一次分析期间没有膀胱癌的患者显示出相同的检查集，在 3 个月后重复进行第二次分析。在这项后续研究中，326 名患者在第二次 UroVysion 测试期间经膀胱镜检查证实为阴性结果。使用中位随访 27 个月评估无复发生存期。结果 在两次连续的 UroVysion 测试中，214 名患者 (65. 6%) 的 UroVysion 结果在两项测试中均呈阴性，而 91 名患者在两项测试中均呈阳性结果，21 名患者在两项测试中均呈阳性结果。在随访期间，40 名患者 (12.3%) 出现非肌肉浸润性膀胱癌的膀胱内复发。两项检测均呈阴性、任一检测均呈阳性的患者以及两项检测均呈阳性的患者的复发率分别为 8.4%、16.5% 和 33.3%。多变量分析表明，膀胱癌病史和连续的 UroVysion 测试模式是复发的独立危险因素。结论 我们的数据证实了连续两次 UroVysion 测试在预测 TURBT 后膀胱内复发方面的有效性。